The HPS6 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T-lymphocyte cell line, designed to disrupt the HPS6 gene encoding a critical subunit of the biogenesis of lysosome-related organelles complex 2 (BLOC-2). This knockout model provides a robust tool for investigating lysosomal trafficking and organelle biogenesis in a T-cell context. The polyclonal population ensures a heterogeneous genetic background, allowing for the study of gene disruption effects without clonal selection biases. The CRISPR/Cas9-mediated gene disruption targets the HPS6 locus to generate a loss-of-function model suitable for a wide range of functional assays.
Jurkat cells are an immortalized human T lymphocyte line originally derived from the peripheral blood of a patient with acute T-cell leukemia. They are widely used as a model system for studying T-cell receptor signaling, cell-mediated immunity, and apoptosis. Their ease of culture and well-characterized signaling pathways make them an ideal host for gene-editing experiments. They are particularly suited for investigating HPS6 in T-cell cytotoxicity and lysosomal-related organelle dynamics.
HPS6 is an essential subunit of the BLOC-2 complex, which mediates cargo sorting from early endosomes to lysosome-related organelles such as melanosomes, platelet dense granules, and lytic granules. The BLOC-2 complex interacts with components like HPS3, HPS5, and the AP-3 adaptor complex, and functions downstream of small GTPases Rab32 and Rab38. Upstream regulatory signals involve transcription factors TFEB and MITF, which respond to lysosomal stress, while downstream effects include proper localization of LAMP1 and LAMP2, and secretion of perforin (PRF1) and granzyme B (GZMB). Disruption of HPS6 impairs these processes, leading to defective organelle biogenesis and functional deficiencies in specialized secretory cell types.
In Jurkat T cells, HPS6 knockout significantly impacts the biogenesis and exocytosis of lytic granules, providing a powerful model for studying T-cell cytotoxicity and degranulation. The loss of HPS6 is expected to mimic aspects of Hermansky-Pudlak syndrome type 6, a disorder characterized by oculocutaneous albinism, platelet storage pool deficiency, and pulmonary fibrosis. Within the Jurkat background, researchers can specifically investigate how BLOC-2 dysfunction affects perforin/granzyme B trafficking, CD107a (LAMP1) surface translocation, and overall lytic capacity. This model is thus highly relevant for dissecting the molecular mechanisms of lysosomal trafficking in immune cells and evaluating potential therapeutic interventions.
Typical research applications include analysis of lysosome-related organelle biogenesis, T-cell degranulation and cytotoxicity, modeling Hermansky-Pudlak syndrome defects, and exploring HPS6’s role in pulmonary fibrosis. Representative assays range from Western blotting for BLOC-2 components and granzyme B, immunofluorescence for LAMP1/2 localization, flow cytometry-based CD107a degranulation assays, to RT-qPCR, lysosomal enzyme activity, electron microscopy, and cytokine profiling. For further information or custom inquiries, contact Ascent Research.
